دورية أكاديمية
Management of neurofibromatosis type 1-associated plexiform neurofibromas
| العنوان: | Management of neurofibromatosis type 1-associated plexiform neurofibromas |
|---|---|
| المؤلفون: | Fisher, Michael J, Blakeley, Jaishri O, Weiss, Brian D, Dombi, Eva, Ahlawat, Shivani, Akshintala, Srivandana, Belzberg, Allan J, Bornhorst, Miriam, Bredella, Miriam A, Cai, Wenli, Ferner, Rosalie E, Gross, Andrea M, Harris, Gordon J, Listernick, Robert, Ly, Ina, Martin, Staci, Mautner, Victor F, Salamon, Johannes M, Salerno, Kilian E, Spinner, Robert J, Staedtke, Verena, Ullrich, Nicole J, Upadhyaya, Meena, Wolters, Pamela L, Yohay, Kaleb, Widemann, Brigitte C |
| المساهمون: | AstraZeneca, Array BioPharma, Exelixis |
| المصدر: | Neuro-Oncology ; volume 24, issue 11, page 1827-1844 ; ISSN 1522-8517 1523-5866 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2022 |
| الوصف: | Plexiform Neurofibromas (PN) are a common manifestation of the genetic disorder neurofibromatosis type 1 (NF1). These benign nerve sheath tumors often cause significant morbidity, with treatment options limited historically to surgery. There have been tremendous advances over the past two decades in our understanding of PN, and the recent regulatory approvals of the MEK inhibitor selumetinib are reshaping the landscape for PN management. At present, there is no agreed upon PN definition, diagnostic evaluation, surveillance strategy, or clear indications for when to initiate treatment and selection of treatment modality. In this review, we address these questions via consensus recommendations from a panel of multidisciplinary NF1 experts. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/neuonc/noac146 |
| DOI: | 10.1093/neuonc/noac146/45048002/noac146.pdf |
| الإتاحة: | https://doi.org/10.1093/neuonc/noac146Test https://academic.oup.com/neuro-oncology/article-pdf/24/11/1827/46694452/noac146.pdfTest |
| رقم الانضمام: | edsbas.1B1BC578 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/neuonc/noac146 |
|---|